ESSA
ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, specializing in the development of innovative therapies for prostate cancer. Founded in 2009, the company is focused on creating small molecule drugs, particularly those that target the N-terminal domain of the androgen receptor (AR). This receptor is crucial for the growth and survival of most prostate cancer cells, making it a key target for advanced hormone therapies. ESSA's lead candidate, EPI-7386, is currently undergoing Phase I clinical trials for the treatment of metastatic castration-resistant prostate cancer. By selectively blocking the AR's N-terminal domain, ESSA aims to address and potentially overcome resistance mechanisms commonly encountered in prostate cancer treatment, thereby offering patients improved progression-free and overall survival outcomes.
Realm Therapeutics is a biopharmaceutical company based in Malvern, Pennsylvania, focused on leveraging proprietary technologies to enhance health outcomes for adults and children. Initially engaged in developing therapies for immune-mediated diseases, the company's drug development efforts are centered on creating small molecule therapies aimed at inflammatory diseases, with applications in dermatology and ophthalmology, as well as potential use in various other conditions. Founded in 2016 and previously known as PuriCore plc, Realm Therapeutics currently operates as a subsidiary of ESSA Pharma Inc. The company is exploring opportunities for investment, partnerships, or acquisitions to further its capabilities in the life sciences sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.